Ryan C. Smith, Ph.D. practices in the area of intellectual property law. Dr. Smith has extensive experience in U.S. and international patent prosecution in the areas of additive manufacturing, biotechnology, antibody engineering, small molecule pharmaceuticals, ag-biotech, chemistry methods, skin care products, inorganic materials science, and diagnostic/therapeutic medical devices. In addition, he has experience in matters directed to non-infringement, invalidity, and freedom-to-operate issues, as well as experience in intellectual property due diligence analysis associated with mergers/acquisitions, public offerings and private equity investments. Dr. Smith works with entrepreneurs, emerging growth companies, university technology transfer offices, and large public U.S. and international companies to identify and develop a comprehensive intellectual property portfolio.
Prior to entering the practice of law, Dr. Smith was a research scientist at Illumina and Amersham/GE Healthcare, where he was involved in projects utilizing organic chemistry, polymer chemistry, materials science, biomaterials, nanotechnology, semiconductor manufacturing, organic light-emitting diodes, antibody conjugates, oligonucleotide synthesis, molecular biology, medical devices, bioanalytical chemistry and DNA sequencing technologies. He was a Postdoctoral Fellow at both Stanford University and IBM-Almaden Research Center, where he researched new polymeric materials for use in semiconductor manufacturing. Dr. Smith is an inventor of a number of patents and has co-authored over 16 scientific articles in peer-reviewed journals.
Dr. Smith is a graduate of the University of San Diego School of Law. He holds a Ph.D. in Chemistry from the University of California at Berkeley and a B.S. in Chemistry from the University of California at San Diego.
Areas of Practice
- Intellectual Property Law
- U.S. Patent and Trademark Office
- University of San Diego School of Law, J.D., 2010
- University of California, Berkeley, Ph.D., Chemistry, 1999
- University of California, San Diego, B.S., Chemistry, 1994
- Duane Morris LLP
- Associate, 2014-present
- UCSD Technology Transfer Office
- Manager, Invention Disclosure Process and Material Transfer Agreements, 2014
- Illumina, Inc.
- Staff Scientist
- GE Healthcare
- Senior R&D Scientist
- Stanford University/IBM Corp.
- Postdoctoral Researcher
- American Chemical Society
- Chair, Law Committee, San Diego Section
- American Intellectual Property Law Association
- San Diego Intellectual Property Law Association
- American Bar Association
Selected Speaking Engagements
Speaker, "Updates to the 21st Century Cures Act," 8th Annual ALS Research Summit, Stanford, CA, January 2018
- Speaker, "Studying the Effects of Marijuana Use," AACC-ACS Joint Meeting, San Diego, September 2017
Co-Organizer, and Presider, Chemistry and the Law Symposium, American Chemical Society National Meeting, San Diego, CA, March 2016
- Organizer, "Biosimilars," American Chemical Society San Diego Law Section Meeting at the Scintillon Research Institution, September 2015
- Presenter, "Processing Invention Disclosures at a University Technology Transfer Office," ACS Western Regional Meeting, November 2015
- "Patent Law for the Scientist-Entrepreneur," The Scripps Research Institute, La Jolla, CA 2015
- "Etiology of University Technology Transfer Patents," 5th Annual ALS Research Summit, San Francisco, CA, 2014
- Contributor, Duane Morris Life Sciences Law Blog
- Co-author, "Highly parallel oligonucleotide purification and functionalization using reversible chemistry," Nucleic Acids Research, 2012 January; 40(1): e4.
- Co-author, "Multiplexed genotyping using a novel digitally inscribed bead-based system," American Society of Human Genetics Conference, Spring 2007
- Co-author, "DNA Separation on Tiny Chips," High Performance Capillary Electrophoresis (HPCE) 16th International Symposium on Microscale Separations and Analysis, San Diego, 2003.
- Co-author, "The effect of surfactants on the reactivity and photophysics of luminescent nanocrystalline porous silicon," Advanced Functional Materials, Volume 12, No. 8, 495-500, 2002.
- Co-author, "The H2-phase of the lyotropic liquid crystal sodium 3,4,5-tris(omega-acryloyloxyundecyloxy)benzoate," Liquid Crystals, Volume 27, Issue 3, 2000, 407-411; DOI: 10.1080/026782900202868
- Co-author, "Advances in the Design of Polymer Nanocomposites Using Polymerizable Lyotropic Liquid Crystals as Matrix Molecules," Poly. Mater. Sci. Eng., Volume 82, 253-254, 2000.
- Co-author, "Structural properties of polymerised lyotropic liquid crystals phases of 3,4,5-tris(?-acryloxyalkoxy)benzoate salts," Macromol. Chem. Phys., 201: 1128-133. doi: 10.1002/1521-3935(20000701)201:11<1128::AID-MACP1128>3.0.CO;2-U
- Co-author, "Synthesis of Functional, Nanostructured Composites and Catalysts using Polymerizable Lyotropic Liquid Crystals," Molecular Crystals and Liquid Crystals, Volume 332, Issue 1, 1999.
- Co-author, "Device characteristics of nanostructured Poly(p-phenylenevinylene)," Synthetic Metals, Volume 102, No. 1-3, 1155-1156, 1999.
- Co-author, "Photophysical properties of nanostructured PPV-composites," Synthetic Metals, Volume 102, Issues 1-3, June 1999, Pages 1270-1271.
- Co-author, "Polymerizable Liquid Crystals as Building Blocks for Functional, Nanostructured Materials," Synlett 1999; 1999(10): 1509-152.
- Co-author, "Optically detected magnetic resonance studies of nanostructured PPV-composites," Optical Materials, Volume 12, Issues 2-3, June 1999, Pages 369-372.
- Co-author, "Structural properties of nanocomposite materials based on a lyotropic liquid crystal," Synthetic Metals, Volume 102, Issues 1-3, June 1999, Pages 1254-1255.
- Co-author, "Synthesis of PPV nanocomposites using lyotropic liquid crystal monomers," Synthetic Metals, Volume 101, Issues 1-3, May 1999, Pages 52-55.
- Co-author, "Efficient full-color electroluminescence and stimulated emission with polyphenylenes," Proc. SPIE, Volume 3476, 76-87, 1998.
- Co-author, "Polymerizable Lyotropic Liquid Crystals Containing Transition-Metal and Lanthanide Ions:? Architectural Control and Introduction of New Properties into Nanostructured Polymers," J. Am. Chem. Soc., 1998, 120 (14), pp 3522-3523; DOI: 10.1021/ja9743654
- Co-author, "Ordered Poly(p-phenylenevinylene) Matrix Nanocomposites via Lyotropic Liquid-Crystalline Monomers," J. Am. Chem. Soc., 1997, 119 (17), pp 4092-4093; DOI: 10.1021/ja963837w
- Issued Patents
- Co-inventor, "Formylpyrrole-based Heterocycles For Nucleic Acid Attachment To Supports," U.S. Patent No. 8,883,764; U.S. Patent No. 9,273,074; U.S. Patent No. 9,475,831
- Co-inventor, "Highly Ordered Nanocomposites via a Monomer Self-Assembly - In Situ Condensation Approach," U.S. Patent No. 5,849,215
- Co-inventor, "Microvessels, microparticles, and methods of manufacturing and using the same," U.S. Patent No. 8,524,450
- Co-inventor, "Functionalization And Purification Of Molecules By Reversible Group Exchange," U.S. Patent No. 9,040,678
- Co-inventor, "Polymer Coatings," U.S. Patent No. 9,012,022
- Co-inventor, "Microvessels, Microparticles, And Methods Of Manufacturing And Using The Same," U.S. Patent No. 9,023,638
- Co-inventor, "Formylpyrrole-based Heterocycles For Nucleic Acid Attachment To Supports," U.S. Patent No. 8,883,764
- Patent Prosecution Counsel to an additive manufacturing company designing rocket engine components.
- Patent Prosecution Counsel to a biopharmaceutical company focusing on ophthalmological treatments.
- Patent Prosecution Counsel to an agricultural biotechnology company.
- Patent Prosecution Counsel to a pharmaceutical company developing small molecule compounds as treatments for cancer.
- Patent Prosecution Counsel to a biotechnology company focusing on fluorescent protein constructs, PCR methods, and oligonucleotide synthesis.
- Patent Prosecution Counsel to a biopharmaceutical company focusing on antibody glyco-engineering, cell-tagging, small molecule anti-viral compounds, and adjuvants.
- Patent Prosecution Counsel to multiple academic institutions prosecuting patents in areas of cancer treatment, drug delivery, biopolymers, and bone repair proteins.